摘要
目的:观察培美曲塞(PEM)联合奈达铂(NDP)治疗铂类敏感的复发上皮性卵巢癌的疗效和不良反应。方法:38例经病理学或细胞学确诊为复发晚期上皮性卵巢癌患者,给予PEM 500mg/m2,NDP 80mg/m2,每21天重复,评价近期疗效及不良反应。结果:38例中无完全缓解(CR)病例,部分缓解(PR)18例,稳定(SD)17例,进展(PD)3例。中位疾病进展期(mTTP)8.3个月,中位生存期(mOS)18.2个月。主要不良副反应为血液学毒性、胃肠道反应、疲劳等。结论:PEM联合NDP治疗复发晚期上皮性卵巢癌疗效确切,耐受性较好。
Objective：To observe the clinical efficacy and adverse reactions of the combination of pemetrexed （PEM） and ncdaplatin （NDP） in treatment of platinum sensitive recurrent advanced epithelial ovarian cancer. Meth- ods ： All 38 cases of recurrent advanced epithelial ovarian cancer patients confirmed histologically or cytologically, giv- en PEM 500mg/m2, and NDP 80mg/m2, repeated every 21 days, to evaluate the efficacy and adverse reactions. Re- suits：There were no complete responses（CR） of the 38 cases, 18 cases achieved partial response（PR）, 17 cases a- chieved stable disease and three patients with progressive disease. The median time to progression（mTTP） and medi- an overall survival（mOS） was 8.3 months and 18.2 months. The major adverse reactions were hematologic toxicity, gastrointestinal reactions and fatigue. Conclusion： PEM combined with NDP is a well - tolerated regimen for platinum -sensitive recurrent epithelial ovarian cancer.
出处
《现代肿瘤医学》
CAS
2013年第12期2791-2792,共2页
Journal of Modern Oncology
关键词
卵巢癌
复发
培美曲塞
奈达铂
ovarian cancer
recurrence
pemetrexed
nedaplatin
